Novavax (NVAX) Change in Accured Expenses (2010 - 2026)

Novavax's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$60.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 71.64% year-over-year to -$60.1 million; the TTM figure through Mar 2026 stood at -$170.8 million (up 47.45% YoY), while the FY2025 annual figure was -$322.6 million, up 16.35% from the prior year.
• Change in Accured Expenses was -$60.1 million for Q1 2026 at Novavax, down from -$21.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $823.0 million in Q4 2022 to a low of -$272.5 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged -$13.7 million across 5 years, with a median of -$60.1 million in 2026.
• Biggest YoY gain for Change in Accured Expenses was 376.12% in 2022; the steepest drop was 316.6% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $823.0 million in 2022, then tumbled by 103.59% to -$29.5 million in 2023, then plunged by 43.74% to -$42.5 million in 2024, then surged by 49.27% to -$21.5 million in 2025, then plunged by 178.87% to -$60.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$60.1 million (Q1 2026), -$21.5 million (Q4 2025), and -$26.5 million (Q3 2025), per Business Quant data.